Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA approves first oral PCSK9 inhibitor for high cholesterol

FDA approves first oral PCSK9 inhibitor for high cholesterol

New Capabilities

Merck's Lipfendra brings injection-strength LDL lowering to a once-daily pill, priced below the shots

July 16th, 2026: FDA approves Lipfendra

Overview

Updated Jul 16

For a decade, the most powerful cholesterol drugs came only as shots. On July 16, 2026, the FDA approved Merck's Lipfendra, a once-daily pill that cut LDL cholesterol about as much as those injections did.

PCSK9 inhibitors cut 'bad' cholesterol by more than half, but the needle and the price kept many patients away. Lipfendra costs $315 a month, below the $500-to-$600 injections. Whether it also prevents heart attacks and strokes won't be confirmed until a large trial reports in 2029.

Why it matters

The strongest cholesterol medicine now comes as a daily pill, cheaper than the shots. If insurers cover it, far more patients could reach it.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

56%
LDL-C reduction
Placebo-adjusted drop at 24 weeks in the CORALreef Lipids trial; 59% in the familial-cholesterol trial.
$315
Monthly price
About $10.50 a tablet, below the $500-to-$600 monthly cost of injectable PCSK9 drugs.
$5B
Peak annual sales estimate
Analyst projection for Lipfendra at its commercial peak.
14,500+
Outcomes trial patients
Enrollment in CORALreef Outcomes, testing whether the pill cuts heart attacks and strokes.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Dean Y. Li
Dean Y. Li
President, Merck Research Laboratories
Led the program behind Merck's first-in-class approval
 Robert M. Davis
Robert M. Davis
Chief Executive Officer, Merck
Counting on new products as Keytruda nears patent loss

Organizations Involved

Merck & Co.
Merck & Co.
Pharmaceutical company
Developer and seller of Lipfendra

The U.S. drugmaker that developed Lipfendra and will sell it.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Reviewed and approved Lipfendra

The U.S. regulator that decides which drugs can be sold in the country.

Timeline

August 2023 December 2029

5 events Latest: July 16th, 2026 · 2 months ago
Tap a bar to jump to that date

  1. Cardiovascular outcomes trial expected to report

    Upcoming Trial

    CORALreef Outcomes is due to show whether the LDL drop translates into fewer heart attacks and strokes, the evidence needed to guide widespread use.

  2. FDA approves Lipfendra

    Latest Approval

    The FDA clears Lipfendra (enlicitide) as the first oral PCSK9 inhibitor, for adults with high LDL cholesterol including inherited high cholesterol. Merck sets the price at $315 a month.

  3. FDA grants a priority review voucher

    Regulatory

    The FDA awards enlicitide a Commissioner's National Priority Voucher, cutting its review from roughly a year to one or two months.

  4. Phase 3 data show the pill matches the shots

    Trial

    CORALreef Lipids results show enlicitide cut LDL-C by about 56% versus placebo at 24 weeks. A separate trial in familial high cholesterol showed a 59% drop.

  5. Merck starts the CORALreef Outcomes trial

    Trial

    Merck begins testing oral enlicitide in more than 14,500 high-risk patients to see whether it prevents heart attacks and strokes. Results are due around December 2029.

Scenarios

1

CORALreef Outcomes confirms Lipfendra cuts heart attacks and strokes

Likely Resolves by Q2 2030

Discussed by: Merck; cardiology researchers cited by AJMC and BioPharma Dive

The 14,500-patient outcomes trial reports a clear reduction in major cardiac events. That result matches earlier injectable PCSK9 outcomes data and pushes the pill into guideline-backed, broad use. It would be the strongest case for insurers to cover it widely.

2

Lipfendra tops $1 billion in annual sales

Possible Resolves by End of 2028

Discussed by: Sell-side analysts cited by CNBC and Fierce Pharma

The pill's convenience and lower price drive fast uptake among patients who avoided injections. Merck's marketing muscle and the drug's antibody-like potency turn it into a blockbuster well before the outcomes data lands. Payer coverage decisions in 2026 and 2027 set the pace.

3

A rival oral PCSK9 pill wins FDA approval

Uncertain Resolves by End of 2028

Discussed by: BioPharma Dive; analysts tracking AstraZeneca's oral PCSK9 program

AstraZeneca and others are developing their own oral PCSK9 inhibitors. A second approval would end Merck's monopoly, add price competition, and speed the shift away from injections. Timing depends on rival trial readouts and FDA review.

4

Outcomes trial fails to show a cardiovascular benefit

Unlikely Resolves by Q2 2030

Discussed by: Cardiologists cautioning that LDL lowering does not guarantee event reduction

The trial confirms the LDL drop but shows no meaningful cut in heart attacks or strokes. That would stall guideline adoption, invite payer pushback, and limit the pill to patients who need aggressive LDL control. It would echo drugs that lowered a marker without helping patients.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1987

First statin approved (1987)

The FDA approved lovastatin (Mevacor) from Merck, the first statin. It was a daily pill that lowered LDL cholesterol by blocking an enzyme the liver uses to make it. Nothing so effective and convenient had existed before.

Then

Statins spread quickly as safe, easy-to-take pills for a common problem.

Now

They became among the most-prescribed drugs in the world and are now cheap generics that anchor cholesterol care.

Why this matters now

A potent oral pill, again from Merck, is what turned cholesterol lowering into mass-scale medicine. Lipfendra aims to do the same for a class stuck behind needles.

July-August 2015

PCSK9 injections launch (2015)

The FDA approved Amgen's Repatha and Regeneron and Sanofi's Praluent, the first PCSK9 inhibitors. Both cut LDL sharply but had to be injected, and both launched near $14,000 a year. Insurers built strict prior-authorization walls.

Then

Early sales badly missed forecasts as payers blocked access and patients balked at the price.

Now

The makers later cut prices by about 60%, and outcomes trials proved the drugs reduce heart attacks, slowly widening use.

Why this matters now

This class works, but injections and price throttled it for years. Lipfendra's lower price and pill form are a direct answer to that history.

September 2019

First oral GLP-1 approved (2019)

The FDA approved Rybelsus (oral semaglutide), the first pill version of a GLP-1 drug for type 2 diabetes, a class that had been injection-only. It proved a large peptide could be formulated into a daily tablet.

Then

The pill expanded a fast-growing class to patients who resisted shots, though it required careful dosing on an empty stomach.

Now

It set the template for turning injectable biologic mechanisms into oral drugs, now a major industry race.

Why this matters now

Lipfendra is another oral take on an injection-only mechanism. Rybelsus shows both the access upside and the practical tradeoffs of moving a peptide into a pill.

Sources

(7)
+1
Merck The American Journal of Managed Care CNBC Fierce Pharma Merck Clinical Trials Pharmacy Times The American Journal of Managed Care